|
| 37423774 | The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. | Eur Urol Oncol | 2024 |
| 36343223 | Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study. | Nutr Cancer | 2023 |
| 38067234 | Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype. | Cancers (Basel) | 2023 |
| 37566643 | Comparing Patient-reported Functional Outcomes After Radical Prostatectomy in Historical and Contemporary Practice. | J Urol | 2023 |
| 35688664 | The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide. | Eur Urol | 2023 |
| 37085424 | Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. | Eur Urol | 2023 |
| 37202314 | 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. | Eur Urol | 2023 |
| 36585434 | MyProstateScore in men considering repeat biopsy: validation of a simple testing approach. | Prostate Cancer Prostatic Dis | 2023 |
| 36842878 | Use of a physical activity monitor to track perioperative activity of radical cystectomy patients. Our first glimpse at what our patients are doing before and after surgery. | Urol Oncol | 2023 |
| 36609003 | Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. | Eur Urol | 2023 |
| 36868882 | Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. | Urol Oncol | 2023 |
| 36600087 | Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. | Nat Rev Urol | 2023 |
| 36795962 | Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. | J Urol | 2023 |
| 36563902 | Mindfulness-based stress reduction for men on active surveillance for prostate cancer and their spouses: Design and methodology of a randomized controlled trial. | Contemp Clin Trials | 2023 |
| 36630135 | Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and Meta-analysis. | JAMA Netw Open | 2023 |
| 36250542 | Characterization of Intercalated Cell Markers KIT and <i>LINC01187</i> in Chromophobe Renal Cell Carcinoma and Other Renal Neoplasms. | Int J Surg Pathol | 2023 |
| 36208697 | Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. | Ann Oncol | 2023 |
| 36264673 | Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates. | Cancer Cytopathol | 2023 |
| 36008540 | Risk of progression following a negative biopsy in prostate cancer active surveillance. | Prostate Cancer Prostatic Dis | 2023 |
| 35878714 | A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for Locally Advanced Prostate Cancer. | Int J Radiat Oncol Biol Phys | 2023 |
| 34285350 | Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. | Prostate Cancer Prostatic Dis | 2022 |
| 35616109 | Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy. | JNCI Cancer Spectr | 2022 |
| 35472327 | Prostate Cancer With Peritoneal Carcinomatosis: A Robotic-assisted Radical Prostatectomy-based Case Series. | Urology | 2022 |
| 35467778 | Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. | Cancer Med | 2022 |
| 35830553 | Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. | J Urol | 2022 |
| 35513774 | Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer. | BMC Cancer | 2022 |
| 35778348 | Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: Perioperative and early oncologic results from the MUSIC statewide collaborative. | Urol Oncol | 2022 |
| 36511267 | Deciphering intratumor heterogeneity in clear cell renal cell carcinoma utilizing clinicopathologic and molecular platforms. | Hum Pathol | 2022 |
| 35963777 | Trials in the Key of G: Building Level 1 Evidence on the Real-world Effectiveness of Prostate Biomarkers. | Eur Urol Focus | 2022 |
| 35900073 | Editorial Comment. | J Urol | 2022 |
| 35930793 | Satisfaction With Clinician-Led Germline Genetic Counseling in Patients With Prostate Cancer. | J Urol | 2022 |
| 36169695 | Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. | World J Urol | 2022 |
| 35984085 | Reply by Authors. | J Urol | 2022 |
| 36386297 | Assessment of prostate cancer progression using a translational needle photoacoustic sensing probe: Preliminary study with intact human prostates <i>ex-vivo</i>. | Photoacoustics | 2022 |
| 35942930 | Delayed urologic cancer care in the COVID-19 pandemic: Patients' experiences. | Eur J Cancer Care (Engl) | 2022 |
| 33655428 | Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes. | World J Urol | 2022 |
| 33812851 | Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. | Eur Urol Oncol | 2022 |
| 34854745 | Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. | J Urol | 2022 |
| 35181282 | Corrigendum to "Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium" [Eur Urol Focus 2021;7:1347-54]. | Eur Urol Focus | 2022 |
| 34906585 | Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. | Urology | 2022 |
| 35201622 | Genetic testing in prostate cancer management: Considerations informing primary care. | CA Cancer J Clin | 2022 |
| 34993496 | Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. | HGG Adv | 2022 |
| 35024633 | Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. | Eur Urol Open Sci | 2022 |
| 34862099 | A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. | Eur Urol | 2022 |
| 34753659 | Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. | Urol Oncol | 2022 |
| 34516660 | Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. | Cancer | 2022 |
| 34840106 | Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature. | Eur Urol Oncol | 2022 |
| 34775795 | Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer. | J Urol | 2022 |
| 32981193 | Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. | BJU Int | 2021 |
| 37145655 | Delayed Urological Cancer Care during the COVID-19 Pandemic: Urologists' Experience. | Urol Pract | 2021 |